Skip to main content

Peer Review reports

From: Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy

Original Submission
26 Mar 2023 Submitted Original manuscript
4 Apr 2023 Author responded Author comments - Wen-Xiong Chen
10 Apr 2023 Reviewed Reviewer Report
5 Jun 2023 Reviewed Reviewer Report
13 Jul 2023 Author responded Author comments - Wen-Xiong Chen
Resubmission - Version 2
4 Apr 2023 Submitted Manuscript version 2
Publishing
26 Jul 2023 Editorially accepted
25 Oct 2023 Article published 10.1186/s12887-023-04212-w

You can find further information about peer review here.

Back to article page